Lexicon Pharmaceuticals Stock In The News

LXRX Stock  USD 2.19  0.21  10.61%   
The tone or emotional content of news articles related to Lexicon Pharmaceuticals can affect its prices. Positive news sentiment can lead to an increase in demand for Lexicon Pharmaceuticals' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Lexicon Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Lexicon Pharmaceuticals. The specific impact of Lexicon Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Lexicon Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Lexicon Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Lexicon Pharmaceuticals Backtesting and Lexicon Pharmaceuticals Hype Analysis.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Lexicon Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
https://finance.yahoo.com/news/3-under-radar-stocks-340-100600678.html
 Neutral
Yahoo News
3 of the Fastest-Growing Stocks on the Planet in 2024
https://finance.yahoo.com/news/3-fastest-growing-stocks-planet-102100990.html
 Neutral
Yahoo News
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 24%
https://finance.yahoo.com/news/lexicon-pharmaceuticals-inc-nasdaq-lxrx-132846736.html
 Bullish
Yahoo News
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/lexicon-pharmaceuticals-provides-business-pipeline-120000992.html
 Neutral
Yahoo News
7 Magnificent Stocks That Can Double Your Money in 2024
https://finance.yahoo.com/news/7-magnificent-stocks-double-money-100600813.html
 Bullish
Yahoo News
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
https://finance.yahoo.com/news/3-growth-stocks-expected-skyrocket-100600514.html
 Bullish
Yahoo News
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
https://finance.yahoo.com/news/lexicon-pharmaceuticals-participate-42nd-annual-211500245.html
 Bullish
Yahoo News
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
https://finance.yahoo.com/news/msclf-aak1-disclosed-drug-target-144600652.html
 Neutral
Macroaxis News: globenewswire.com
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
https://www.globenewswire.com/news-release/2023/11/30/2788490/0/en/Lexicon-Enrolls-First-Patient-in-Phase-2b-Progress-Study-of-LX9211-in-Diabetic-Peripheral-Neuropathic-Pain-DPNP.html
 Bullish
Yahoo News
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
https://finance.yahoo.com/news/lexicon-enrolls-first-patient-phase-123000220.html
 Bullish

Lexicon Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Lexicon and other traded companies coverage. We help investors stay connected with Lexicon headlines for the 28th of March to make an informed investment decision based on correlating the impacts of news items on Lexicon Stock performance. Please note that trading solely based on the Lexicon Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Lexicon Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Lexicon Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Lexicon Pharmaceuticals noise-free hype analysis.
Lexicon Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Lexicon earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Lexicon Pharmaceuticals that are available to investors today. That information is available publicly through Lexicon media outlets and privately through word of mouth or via Lexicon internal channels. However, regardless of the origin, that massive amount of Lexicon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lexicon Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lexicon Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lexicon Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lexicon Pharmaceuticals alpha.

Lexicon Largest EPS Surprises

Earnings surprises can significantly impact Lexicon Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-11-03
2021-09-30-0.18-0.160.0211 
2023-03-02
2022-12-31-0.13-0.16-0.0323 
2021-07-30
2021-06-30-0.16-0.130.0318 
2016-05-03
2016-03-31-0.3-0.34-0.0413 
2023-08-03
2023-06-30-0.17-0.22-0.0529 
2018-05-03
2018-03-31-0.45-0.40.0511 
View All Earnings Estimates

Lexicon Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Lexicon Pharmaceuticals Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
12th of March 2024
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control Wit...
at finance.yahoo.com 
Yahoo News
11th of March 2024
Lexicon Announces Oversubscribed 250 Million Private Placement of Equity Securities
at finance.yahoo.com 
Yahoo News
29th of February 2024
Y-mAbs Therapeutics, Inc. Reports Q4 Loss, Tops Revenue Estimates
at finance.yahoo.com 
Google News at Macroaxis
28th of February 2024
Disposition of 33333 shares by Lonnel Coats of Lexicon Pharmaceuticals subject to Rule 16b...
at news.google.com 
news
22nd of February 2024
Lexicon Pharmaceuticals Sees Strong Trading Volume
at thelincolnianonline.com 
Google News at Macroaxis
26th of January 2024
Is Lexicon Pharmaceuticals Inc Stock Worth a Buy Friday - InvestorsObserver
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lexicon Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lexicon Pharmaceuticals' short interest history, or implied volatility extrapolated from Lexicon Pharmaceuticals options trading.
When determining whether Lexicon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexicon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexicon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexicon Pharmaceuticals Stock:
Check out Lexicon Pharmaceuticals Backtesting and Lexicon Pharmaceuticals Hype Analysis.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Lexicon Stock analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.80)
Revenue Per Share
0.005
Quarterly Revenue Growth
24.071
Return On Assets
(0.51)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.